These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32861832)

  • 41. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
    PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
    Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
    Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lectibodies as antivirals.
    Santisteban Celis IC; Matoba N
    Antiviral Res; 2024 Jul; 227():105901. PubMed ID: 38734211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
    Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
    Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
    Yokokawa H; Shinohara M; Teraoka Y; Imamura M; Nakamura N; Watanabe N; Date T; Aizaki H; Iwamura T; Narumi H; Chayama K; Wakita T
    PLoS One; 2022; 17(9):e0274283. PubMed ID: 36137152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Role for B Cells to Transmit Hepatitis C Virus Infection.
    Desombere I; Van Houtte F; Farhoudi A; Verhoye L; Buysschaert C; Gijbels Y; Couvent S; Swinnen W; Van Vlierberghe H; Elewaut A; Magri A; Stamataki Z; Meuleman P; McKeating JA; Leroux-Roels G
    Front Immunol; 2021; 12():775098. PubMed ID: 34975862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    Bukh J
    J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Desombere I; Fafi-Kremer S; Van Houtte F; Pessaux P; Farhoudi A; Heydmann L; Verhoye L; Cole S; McKeating JA; Leroux-Roels G; Baumert TF; Patel AH; Meuleman P
    Hepatology; 2016 Apr; 63(4):1120-34. PubMed ID: 26710081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
    Colpitts CC; Baumert TF
    Hepatol Int; 2016 Sep; 10(5):741-8. PubMed ID: 27048616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    Merat SJ; Bru C; van de Berg D; Molenkamp R; Tarr AW; Koekkoek S; Kootstra NA; Prins M; Ball JK; Bakker AQ; de Jong MD; Spits H; Beaumont T; Schinkel J
    J Hepatol; 2019 Jul; 71(1):14-24. PubMed ID: 30797052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
    Örmeci N; Gülşen MT; Sezgin O; Aghayeva S; Demir M; Köksal I; Güner R; Erarslan E; Asiller ÖÖ; Balkan A; Yaraş S; Çalışkan Kartal A
    Turk J Gastroenterol; 2020 Feb; 31(2):148-155. PubMed ID: 32141824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
    Lacek K; Vercauteren K; Grzyb K; Naddeo M; Verhoye L; Słowikowski MP; Fafi-Kremer S; Patel AH; Baumert TF; Folgori A; Leroux-Roels G; Cortese R; Meuleman P; Nicosia A
    J Hepatol; 2012 Jul; 57(1):17-23. PubMed ID: 22414763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.